Advanced Lipid Testing in Philadelphia, PA: ApoB, Lp(a), and What Beats the Standard Panel

The cardiovascular literature has been telling clinicians to update the lipid panel for over a decade. The European cardiology guidelines moved to ApoB-preferred targets in 2019. The American guidelines now include ApoB and Lp(a) as appropriate to measure. In practice, most Philadelphia primary care practices still order the standard panel and stop there. This page explains what advanced lipid testing in Philadelphia actually means, why it matters, and how Fishtown Medicine uses it.

What's in the standard panel and why it's incomplete

The standard cholesterol panel in Philadelphia primary care typically reports:

• Total cholesterol
• LDL-C (low-density lipoprotein cholesterol)
• HDL-C
• Triglycerides
• Calculated non-HDL cholesterol

LDL-C is the centerpiece. The clinical problem is that LDL-C is usually a calculated value (from the Friedewald or Martin-Hopkins equation), not a direct measurement, and it measures the cholesterol content of LDL particles, not the number of particles. Two patients can have the same LDL-C but different cardiovascular risk if one has many small particles and the other has fewer large ones. ApoB resolves this by counting particles directly.

ApoB: the marker that actually predicts risk

Apolipoprotein B (ApoB) is a protein found in the atherogenic particles (LDL, VLDL, IDL, Lp(a)). Each particle has exactly one ApoB molecule. So measuring ApoB gives you a direct count of the particles that drive atherosclerosis. Multiple large studies (most clearly the work from Sniderman and Jukema) show that ApoB outperforms LDL-C as a predictor of cardiovascular events. The European Society of Cardiology guidelines moved to ApoB-preferred targets in 2019. The American guidelines now permit ApoB as an alternative to LDL-C. Target ApoB ranges by risk:

• Low risk: under 90 mg/dL
• Moderate risk (most adults): under 80 mg/dL
• High risk (existing cardiovascular disease, diabetes, multiple risk factors): under 65 mg/dL
• Very high risk: under 50 mg/dL

These targets are assertive by traditional standards but match the modern evidence.

Lp(a): the once-in-a-lifetime test most patients have never had

Lipoprotein(a), or Lp(a), is a genetically-determined particle that combines an LDL-like core with a covalently bound apolipoprotein(a). Elevated Lp(a) is an independent cardiovascular risk factor: people with high Lp(a) have substantially elevated risk of heart attack, stroke, and aortic valve disease. The key facts:

• Lp(a) is largely genetic. Your level is set in childhood and changes little throughout adult life.
• It is not strongly modifiable by diet, exercise, or standard lipid-lowering therapy.
• About 20% of adults have elevated Lp(a) (above 50 mg/dL or 100 nmol/L).
• Most patients have never had it tested.
• It changes prevention strategy when elevated: more assertive ApoB targets, more attention to other modifiable risk factors, earlier screening for aortic valve disease.

The screening recommendation: test Lp(a) at least once in every adult's lifetime. We test it on every new adult patient at Fishtown Medicine.

Other advanced lipid measurements

LDL particle number (LDL-P) by NMR. Measures particles by nuclear magnetic resonance. Conceptually similar to ApoB. We generally prefer ApoB because it captures all atherogenic particles, not just LDL. Particle size (small vs. large LDL). Smaller particles are more atherogenic. Useful in some contexts but ApoB already captures most of the relevant information. hsCRP. High-sensitivity C-reactive protein measures low-grade inflammation. Elevated hsCRP independently raises cardiovascular risk. We typically include it in the panel.

Homocysteine. Modest independent risk factor; treatable with B vitamins. We sometimes include it. Cardiac imaging, after the upstream read. Our preference is to read ApoB, particle fractionation, Lp(a), and family history first, then decide on imaging. CAC (coronary artery calcium) reads calcified plaque only and runs roughly $150 cash at most Philadelphia imaging centers. CCTA (coronary CT angiography, increasingly with Cleerly AI analysis) is the more sensitive imaging step for soft plaque - the kind that ruptures and causes most heart attacks. For patients with intermediate cardiovascular risk, one of these is often the right next step.

Where to get advanced lipid testing in Philadelphia

LabCorp and Quest both offer ApoB, Lp(a), and most other advanced lipid markers. Both have draw stations throughout Philadelphia (Center City, Fishtown, University City, Northeast, suburbs). Insurance coverage:

• ApoB: increasingly covered as a standard lipid marker.
• Lp(a): increasingly covered, especially when family history of cardiovascular disease is documented.
• hsCRP: usually covered with appropriate indication.

Self-pay pricing (approximate):

• ApoB: $20-40
• Lp(a): $30-60
• hsCRP: $20-40
• Comprehensive advanced panel (ApoB, Lp(a), particle analysis, hsCRP): $100-200

How advanced lipid testing fits into Fishtown Medicine's preventive workup

We run ApoB on every adult patient at the first preventive visit and serially as we manage cardiovascular risk. We run Lp(a) once in a lifetime on every adult patient. We include hsCRP in the standard panel. We use ApoB-based targets for prevention, not LDL-based ones. We do not chase LDL targets when ApoB is the better marker. For patients with elevated Lp(a) or other concerning advanced lipid findings, we move to more assertive prevention: ApoB target lower than otherwise, CAC scan to assess atherosclerotic burden, attention to other modifiable risk factors, earlier screening for valve disease in some cases.

What it costs

Membership at Fishtown Medicine covers all visits and ongoing management; see pricing for current rates. The interpretation and longitudinal management of advanced lipid testing is covered in the membership. The labs themselves are billed at the cheapest of insurance or cash.

Key Takeaways

• ApoB outperforms LDL-C for cardiovascular risk prediction.
• Lp(a) should be measured at least once in every adult's lifetime.
• Both are widely available in Philadelphia and increasingly insurance-covered.
• Fishtown Medicine uses ApoB-based targets and integrates advanced lipid testing into ongoing primary care.

Related Services and Reading

• Preventive Care in Philadelphia
• Longevity Medicine in Philadelphia
• Executive Physical in Philadelphia
• ApoB and Heart Health
• Lp(a) Cholesterol
• ApoB vs LDL
• Direct Primary Care in Philadelphia
• DEXA Scan - body composition and bone density measurement
• Continuous Glucose Monitor (CGM) - real-time glucose data for metabolic optimization
• VO2 Max Testing - the strongest single predictor of all-cause mortality

---